---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-26-000040"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T05:01:33.538514+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reiterates FY2025 results: $8.2M cash, $12M loss; raises $6.5M, runway into Q1 2027

## Summary
- Cash and cash equivalents of $8.2M at Dec 31, 2025; raised additional $6.5M in Jan 2026 via ATM offering.
- Net loss for FY2025 was $12M; R&D expenses increased to $6.8M from $3.8M year-over-year.
- Cash runway expected to fund planned operations into the first quarter of 2027.
- Positive Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis reinforces clinical proof-of-concept.
- Advancing GRI-0803 for autoimmune indications through IND-enabling studies.

## SEC filing metadata
- accession: 0001824293-26-000040
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429326000040/0001824293-26-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429326000040/val-20260204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-26-000040
- JSON: https://secwatch.observer/filing/0001824293-26-000040.json
- Plain text: https://secwatch.observer/filing/0001824293-26-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.